Sagimet Biosciences Inc.
Sagimet develops FASN inhibitors for metabolic and fibrotic diseases driven by palmitate overproduction, including acne, MASH, and FASN-dependent tumors.
8-KOct 1Latest SEC filing, period to Sep 30
Sep 30Latest story
Sign inSign inSagimet develops FASN inhibitors for metabolic and fibrotic diseases driven by palmitate overproduction, including acne, MASH, and FASN-dependent tumors.